[CITATION][C] Emergence of a squamous cell carcinoma phenotype following treatment of metastatic basal cell carcinoma with vismodegib
A Iarrobino, JL Messina, R Kudchadkar… - Journal of the American …, 2013 - jaad.org
To the Editor: Vismodegib is a small molecule inhibitor of the hedgehog signaling pathway
approved by the US Food and Drug Administration (FDA) for the treatment of basal cell
carcinoma (BCC) as of January 2012, 1 and phase I clinical trial results were recently
published. 2 Given the potential for its widespread use, possible unexpected outcomes are
pertinent to dermatologists and oncologists. A case of squamous cell carcinoma (SCC)
emerging after treatment of metastatic BCC with vismodegib is described. A 61-year-old man …
approved by the US Food and Drug Administration (FDA) for the treatment of basal cell
carcinoma (BCC) as of January 2012, 1 and phase I clinical trial results were recently
published. 2 Given the potential for its widespread use, possible unexpected outcomes are
pertinent to dermatologists and oncologists. A case of squamous cell carcinoma (SCC)
emerging after treatment of metastatic BCC with vismodegib is described. A 61-year-old man …